Adjuvant Therapy of Uveal Melanoma: Current Status

  • Triozzi P
  • Singh A
N/ACitations
Citations of this article
42Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The survival of patients with uveal melanoma remains poor because of the development of metastatic disease. Adjuvant therapy after treatment of the primary tumor has been tested but has not been shown to prevent the development of metastasis. Several new approaches are being developed. Cytotoxic and immunotherapeutic regimens are being more rationally applied using tumor genetic criteria to better identify patients at risk. Trials in the adjuvant setting of novel immunotherapeutic and targeted agents active in the metastatic setting are being developed, as are approaches to promote cellular differentiation and dormancy. The rarity and biology of uveal melanoma present challenges. Participation in well-designed, scientifically sound clinical trials is critical.

Cite

CITATION STYLE

APA

Triozzi, P. L., & Singh, A. D. (2015). Adjuvant Therapy of Uveal Melanoma: Current Status. Ocular Oncology and Pathology, 1(1), 54–62. https://doi.org/10.1159/000367715

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free